{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-006191","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2025-01-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.164949+00:00","generated_at":"2026-05-28T00:02:57.402659+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Atara receives FDA Complete Response Letter for EBVALLO BLA due to third-party manufacturing issues","bullets":["FDA CRL solely related to third-party manufacturer inspection findings; no clinical efficacy/safety issues, no new trials requested.","Atara expects resubmission within 6 months after GMP compliance resolved; potential approval within 6 months of resubmission.","Preliminary cash and investments ~$43M as of Dec 31, 2024; non-binding term sheet with Redmile for up to $15M equity line.","Atara exploring strategic alternatives; may suspend CAR-T activities if no funding by Q1 2025; committed to preserving EBVALLO value.","Atara remains eligible for $60M milestone from Pierre Fabre upon FDA approval and double-digit royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-006191","json":"https://secwatch.observer/filing/0000950170-25-006191.json","markdown":"https://secwatch.observer/filing/0000950170-25-006191.md","text":"https://secwatch.observer/filing/0000950170-25-006191.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000095017025006191/0000950170-25-006191-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000095017025006191/atra-20250116.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T00:02:57.402659+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}